BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA.OB) announced that the Company has filed an appeal of the recent negative decision by the Food and Drug Administration’s (FDA) Office of Oncology Drug Products (OODP) regarding the Company’s New Drug Application (NDA) for Genta’s lead oncology product, Genasense® (oblimersen sodium) Injection. The NDA proposed the use of Genasense in combination with chemotherapy as treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
